All News

RheumNow Podcast square

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.

Read Article
PSA Panel

TNR Recap: What Patients Say about PsA

Jack Cush, MD

Watch this outstanding and informative Tuesday Nite Rheumatology, held on April 5th, 2022 which featured a Patient Perspectives panel discussion, hosted by Dr. Jack Cush.



PsA Panelists included:



- Tena Brown



- Christine Lindsay



- Ashley Krivohlavek


Read Article
Sausage061.jpg

Dactylitis Indicates a Severe PsA Phenotype

Jack Cush, MD

A recent study analyzed the impact of dactylitis in disease-modifying antirheumatic drug (DMARD)-naive early psoriatic arthritis (PsA) and found that DMARD-naive PsA patients with dactylitis (dactylitic PsA) have a greater burden of disease than those without dactylitis. 

Read Article
heart,cv,meds, events, CVD

Apremilast’s Neutral Effects on Cardiovascular Inflammation

MedPage Today

An evaluation of a common psoriasis drug's effect on one cardiometabolic risk factor instead showed a favorable impact on a different one.

Read Article
psoriasis,arms,pain

Towards More Uniform Methotrexate Dosing in Psoriasis

MedPage Today

With overwhelming support from some 200 experts worldwide, dosing of methotrexate (MTX) for psoriasis should start at 15 mg/week for most adults, though lower in those considered "vulnerable" and in children, according to a new consensus statement.

Read Article
CorEvitas Registry study of Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted in modest, nonsignificant improvement axial outcomes,(irrespective HLA-B27 status), including ASDAS40, BASDAI50, & spinal pain. 31% of pts were B27+ https://t.co/9m9H7PwIIF #PsAlways https://t.co/dYk5GfIdez

Links:

Dr. John Cush RheumNow ( View Tweet)
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/Hc4rNrlQzP https://t.co/UPosZIc4C0

Links:

Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/0nvutsXHsI https://t.co/jh43zCbdZx

Links:

Dr. John Cush RheumNow ( View Tweet)
Differences between Palpated & Ultrasound Joint exams in 155 #PSA patients. 5616 joints - found 18.5% tender, 9.8% swollen, 20.4% w/ US GS ≥ 2 and 5.2% had US PD ≥ 1. Joints that were both tender and swollen more likely to have GS ≥ (44%) https://t.co/nWI7jLdkWp https://t.co/iRNsqWYScM

Links:

Dr. John Cush RheumNow ( View Tweet)
Dactylitis Indicates a Severe PsA Phenotype https://t.co/bUg15czr1Q https://t.co/bnawRJ20jj

Links:

Dr. John Cush RheumNow ( View Tweet)
Among 1033 #PSA pts - 37% were obese. Obese PsA pts had higher PsAQoL, HADS-Anxiety, HADS-Depression, DAPSA, DAS28-CRP, BASDAI, BASFI, HAQ &FACIT scores (p<0.05). BMI affects QOL, depression, disease activity, fatigue https://t.co/6PD8G6xFnk https://t.co/Wlgp0gJGbK

Links:

Dr. John Cush RheumNow ( View Tweet)
This week's Daily Download includes 9 slides covering Moll & Wright classification; epidemiology & prevalence; factors; skin & joint images, and more. https://t.co/Pr7vODmmnr https://t.co/TEzUy5r4rZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Australian study from 2 #PSA clinics PsA clinics compared RAPID3 score to MDA, very low disease activity (VLDA) & DAPSA. 93 pts showed RAPID3 correlated w/ ROC AUC for VLDA (0.94) and DAPSA (0.96) https://t.co/x9G8wTpeS6 #PsAlways https://t.co/WuseKMoiJj

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic Does the Moll & Wright Classification of PsA hold up? QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/zskcsZ4kkW https://t.co/QZOb09wGyp

Links:

Dr. John Cush RheumNow ( View Tweet)
Network metaanalysis studied 46 RCTs biologics in #PsA. Some TNFi's numerically (not signif) better vsn interleukin inhib for ACR resps, but worse on PASI resps (IL-23, IL-17i had better PASI responses); No diff in enthesitis & dactylitis resps https://t.co/AvnoLRVi6C #PsAlways https://t.co/BSl9hVbIx6

Links:

Dr. John Cush RheumNow ( View Tweet)
Your Psoriatic Questions from RNL 2022 Dr. Jack Cush fields Rheumatologists questions from RNL 2022 QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022. https://t.co/DlW5KA3mEo https://t.co/wtTlYJs89l

Links:

Dr. John Cush RheumNow ( View Tweet)
Towards More Uniform Methotrexate Dosing in Psoriasis https://t.co/3GrJADizKK https://t.co/jMAQO5D5Zz

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us for Tuesday Night Rheumatology on April 5 at 7pm ET. Register today! https://t.co/khydENTDzr https://t.co/mtlfIeyRpc

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA All the Way – All April Long Join us all April long for our focus on PsA. Tweets, articles, blogs, therapeutic updates and more...all this month! https://t.co/KEDx73TYHL https://t.co/GaTZ00dQ4N

Links:

Dr. John Cush RheumNow ( View Tweet)
#PsA Biologic initiation was associated with a SMALL drop in NSAIDs (51.1 to 42.5%); glucocorticoids (57.4 to 46.9%) and opioids (38.1 to 33.8%) (Initial vs 12 mos later). Pain Rx use study in 5681 PsA, 2180 AS, & 34,047 RA pts #PsAlways https://t.co/wyrT9CVNq8 https://t.co/8vl7e2a63n

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×